Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M341Revenue (TTM) $M22.3Net Margin (%)-360.9Altman Z-Score-1.8
Enterprise Value $M283EPS (TTM) $-3.3Operating Margin %-356.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.2Pre-tax Margin (%)-360.7Higher ROA y-yN
Price/Book3.410-y EBITDA Growth Rate %--Quick Ratio4.9Cash flow > EarningsY
Price/Sales15.25-y EBITDA Growth Rate %--Current Ratio5.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-32.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-58.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.8ROIC % (ttm)-150.5Gross Margin Increase y-yY

Gurus Latest Trades with ZGNX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ZGNX is held by these investors:



ZGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PERCEPTIVE LIFE SCIENCES MASTE10% Owner 2017-06-30Buy175,653$14.45-4.98view
TANNENBAUM RENEE PDirector 2017-03-16Buy5,000$1124.82view
HAWLEY ROGERDirector 2015-12-15Buy10,000$13.74-0.07view
HAWLEY ROGERDirector 2015-12-15Buy10,000$13.74-0.07view
TANNENBAUM RENEE PDirector 2015-12-03Buy5,000$15.4-10.84view
HAWLEY ROGERDirector 2015-06-16Buy6,250$12.727.94view
HAWLEY ROGERCEO 2015-03-16Buy17,500$10.4831.01view
GARNER CAM LDirector 2014-06-13Buy3,750$13.283.39view
Shively Richard ScottChief Commercial Officer 2014-06-03Sell2,404$16.8-18.27view
RHOADS ANN DEVP, CFO, Treasurer & Sec. 2014-06-03Sell2,404$16.8-18.27view

Press Releases about ZGNX :

Quarterly/Annual Reports about ZGNX:

News about ZGNX:

Articles On GuruFocus.com
Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome Jun 22 2017 
Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board Jun 14 2017 
Zogenix to Present at the Jefferies 2017 Global Healthcare Conference May 31 2017 
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results May 04 2017 
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome Apr 27 2017 
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May Apr 27 2017 
Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference Mar 15 2017 
Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Mar 02 2017 
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome Mar 01 2017 
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 

More From Other Websites
Zogenix, Inc. breached its 50 day moving average in a Bearish Manner : ZGNX-US : July 19, 2017 Jul 19 2017
The Chance to Sidestep a Marijuana Medicine Sent This Stock Soaring 14% in June Jul 07 2017
Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome Jun 22 2017
Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board... Jun 14 2017
ETFs with exposure to Zogenix, Inc. : June 8, 2017 Jun 08 2017
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals? Jun 05 2017
Zogenix to Present at the Jefferies 2017 Global Healthcare Conference May 31 2017
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of... May 22 2017
ETFs with exposure to Zogenix, Inc. : May 11, 2017 May 11 2017
Edited Transcript of ZGNX earnings conference call or presentation 4-May-17 8:30pm GMT May 11 2017
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Zogenix reports 1Q loss May 04 2017
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results May 04 2017
Investor Network: Zogenix, Inc. to Host Earnings Call May 04 2017
Blog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome May 01 2017
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome Apr 27 2017
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May... Apr 27 2017
ETFs with exposure to Zogenix, Inc. : April 17, 2017 Apr 17 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}